Review of targeted treatments in fragile X syndrome

Andrew Ligsay, Randi J Hagerman

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.

Original languageEnglish (US)
Pages (from-to)158-167
Number of pages10
JournalIntractable and Rare Diseases Research
Volume5
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Fragile X Syndrome
GABA Modulators
Fragile X Mental Retardation Protein
Clinical Trials
Excitatory Amino Acid Antagonists
Metabotropic Glutamate Receptors
GABA Receptors
Intellectual Disability
Therapeutics
Genes

Keywords

  • Clinical trials
  • Fragile X syndrome
  • Targeted treatments

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Review of targeted treatments in fragile X syndrome. / Ligsay, Andrew; Hagerman, Randi J.

In: Intractable and Rare Diseases Research, Vol. 5, No. 3, 2016, p. 158-167.

Research output: Contribution to journalReview article

@article{318dff5ab00e49d5ab8f2fc6f97495ca,
title = "Review of targeted treatments in fragile X syndrome",
abstract = "Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.",
keywords = "Clinical trials, Fragile X syndrome, Targeted treatments",
author = "Andrew Ligsay and Hagerman, {Randi J}",
year = "2016",
doi = "10.5582/irdr.2016.01045",
language = "English (US)",
volume = "5",
pages = "158--167",
journal = "Intractable and Rare Diseases Research",
issn = "2186-3644",
publisher = "International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)",
number = "3",

}

TY - JOUR

T1 - Review of targeted treatments in fragile X syndrome

AU - Ligsay, Andrew

AU - Hagerman, Randi J

PY - 2016

Y1 - 2016

N2 - Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.

AB - Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.

KW - Clinical trials

KW - Fragile X syndrome

KW - Targeted treatments

UR - http://www.scopus.com/inward/record.url?scp=85018234013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018234013&partnerID=8YFLogxK

U2 - 10.5582/irdr.2016.01045

DO - 10.5582/irdr.2016.01045

M3 - Review article

AN - SCOPUS:85018234013

VL - 5

SP - 158

EP - 167

JO - Intractable and Rare Diseases Research

JF - Intractable and Rare Diseases Research

SN - 2186-3644

IS - 3

ER -